Inozyme Pharma, Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Inozyme Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
  • Inozyme Pharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 55.1 %, a 78.9% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 55.1 +24.3 +78.9% Sep 30, 2024
Q2 2024 43.8 +17 +63.6% Jun 30, 2024
Q1 2024 39.9 +21.8 +121% Mar 31, 2024
Q4 2023 37.2 +23.6 +174% Dec 31, 2023
Q3 2023 30.8 +18.3 +146% Sep 30, 2023
Q2 2023 26.8 +15.6 +140% Jun 30, 2023
Q1 2023 18.1 +7.21 +66.5% Mar 31, 2023
Q4 2022 13.6 +4.79 +54.3% Dec 31, 2022
Q3 2022 12.5 +4.98 +66.1% Sep 30, 2022
Q2 2022 11.2 +4.28 +62% Jun 30, 2022
Q1 2022 10.9 +1.59 +17.2% Mar 31, 2022
Q4 2021 8.82 Dec 31, 2021
Q3 2021 7.54 Sep 30, 2021
Q2 2021 6.91 Jun 30, 2021
Q1 2021 9.26 Mar 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.